Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 10 companies, including Dongshan Precision (002384), which is preparing for a listing on the Hong Kong Stock Exchange [1][2] Group 1: Regulatory Requirements - Dongshan Precision is required to provide detailed explanations regarding its medical device production, commission agency, IT and socio-economic consulting services, solar product system installation and sales, and solar industrial technology research consulting services, including necessary qualifications and licenses [1] - The company must clarify whether its business scope involves areas listed in the "Special Management Measures for Foreign Investment Access (Negative List) (2024 Edition)" [1] - Dongshan Precision is asked to explain the pledge status of shares held by its controlling shareholders and actual controllers before and after the issuance, and whether this could lead to significant ownership disputes or changes in control [1] - The company needs to detail the compliance status of its overseas subsidiaries regarding foreign investment and foreign exchange registration procedures, providing conclusive legal opinions [1] Group 2: Company Profile - Dongshan Precision is recognized as the world's largest PCB supplier for edge AI devices, with products primarily used in smartphones, personal computers, automobiles, industrial applications, and IoT devices, and is rapidly expanding its capabilities into the data center terminal market [2]

证券日报网讯1月9日，硕世生物在互动平台回答投资者提问时表示，截至2025年12月31日，公司股东总 数为7302户。 ...

万孚生物表示，公司归属净利润同比下滑，有以下几方面原因，一是由于国内市场终端降价、产品结构 变化，合并报表毛利率下降；二是公司为了夯实产品竞争力，开拓新市场、新应用场景，仍然维持了较 高的研发支出和销售费用；三是对于非核心的、盈利能力较弱的业务进行剥离，产生了一定的减值损 失。 北京商报讯（记者 丁宁）1月9日晚间，万孚生物（300482）发布2025年业绩预告显示，公司2025年预 计归属净利润为4600万元至6900万元，同比预降87.71%至91.81%。 ...

证券日报网讯 1月9日，海尔生物在互动平台回答投资者提问时表示，近年来受到复杂多变的全球和行 业形势等因素影响，公司业绩有所波动。今年前三季度，公司展现出较强的发展韧性，业绩于第二季度 触底后，在第三季度实现反弹，新产业占公司主营业务收入的比重已提升至48%；海外市场表现尤其亮 眼，今年前三季度收入增幅达20%、占公司主营业务收入的比重为36%，而过去六年来公司海外业务复 合增长率为25%，海外市场竞争力为公司业绩持续复苏提供了重要支撑。此外，公司持续推进"AI+"与 四大产业的深度融合，为公司市场份额提升和用户价值创造提供重要支撑，数智自动化样本方案前三季 度实现了翻番增长。未来，公司将继续坚持技术创新、场景升级和全球化发展，并加强与投资者的交 流。 （文章来源：证券日报） ...

Core Viewpoint - Haier Biomedical has outlined its four major industry layouts, focusing on providing comprehensive biological safety solutions and integrated management systems across various healthcare and research sectors [2] Group 1: Industry Layouts - The low-temperature storage industry targets biological objects such as samples, pharmaceuticals, vaccines, and blood, offering solutions that cover a temperature range from -196°C to 8°C [2] - The laboratory solutions industry serves users in research, pharmaceuticals, and testing, providing comprehensive solutions that include general instruments, analytical instruments, consumables, and software [2] - The blood technology industry focuses on whole blood and component blood collection and preparation, offering intelligent solutions for blood stations and plasma stations, including collection equipment, consumables, and pharmaceuticals [2] - The smart medication industry addresses the full-process automated management needs of hospital pharmacies, inpatient pharmacies, infusion centers, and fever clinics, providing solutions for drug "transfer-distribution-use" [2]

招股书显示，博迈医疗专注于高性能血管介入医疗器械的研发、生产及全球销售，是全球行业内技术及 产品领先的复杂血管疾病介入治疗解决方案提供商，同时也是国产血管介入球囊导管领域产销量领先的 研发生产企业。 此次创业板IPO，博迈医疗拟募集资金17亿元，投向松山湖全球总部项目、湖南生产基地技改（一期） 项目、介入类医疗器械研发项目等5个项目。 北京商报讯（记者 丁宁）深交所官网显示，广东博迈医疗科技股份有限公司（以下简称"博迈医疗"） 创业板IPO进入已问询阶段。 ...

北京商报讯（记者 丁宁）1月9日，国家药监局官网显示，根据《医疗器械标准管理办法》《医疗器械 标准制修订工作管理规范》要求，国家药监局经公开征求意见和组织专家论证，确定了《采用脑机接口 技术的医疗器械 侵入式设备 可靠性验证方法》等2项推荐性医疗器械行业标准制订计划，并予以公示。 ...

Core Viewpoint - The company emphasizes that technological self-reliance is driving the industry towards domestic production, which further expands its development space and enhances market competitiveness across its four major industries [1] Market Position and Performance - The company's market share in the low-temperature storage industry continues to increase, with a projected market share of over 50% in plasma collection solutions by mid-2025, based on public and third-party bidding data [1] - The company ranks among the top three in the automated medication market and continues to break through in the domestic market for scientific instruments, with its total organic carbon analyzers and UV spectrophotometers being the top two domestic brands [1] - The centrifuge series has entered the top ten in market share among industry brands, while the biological safety cabinet has risen to the number one position nationwide, and the cultivation series maintains the highest market share among domestic brands [1] International Market Presence - Preliminary market research indicates that the company's three major low-temperature product lines hold the leading market share in 25 overseas countries [1]

Group 1 - JD Health held the 2026 Medical Device Development Strategy Conference, focusing on supply, AI, and medical services as core drivers for growth [1] - The company signed agreements with the top 100 global brands to launch new products in 2026, committing over 100 million in marketing resources [1] - JD Health aims to enhance its medical device sector by leveraging its supply chain, AI technology, and internet medical services to create a comprehensive ecosystem [1] Group 2 - In 2025, JD Health plans to deepen global brand collaborations and introduce overseas supplies through large-scale procurement [2] - The company will focus on high-potential areas such as chronic disease management and home healthcare, aiming to transition from single product sales to comprehensive health management solutions [2] - JD Health is committed to driving innovation and sustainable development in the medical device industry by enhancing product offerings and AI technology [2]

该股主要指标及行业内排名如下： 迈得医疗2025年三季报显示，前三季度公司主营收入2.25亿元，同比上升2.31%；归母净利润883.67万 元，同比上升15.82%；扣非净利润-127.85万元，同比下降526.58%；其中2025年第三季度，公司单季度 主营收入8364.3万元，同比上升54.38%；单季度归母净利润279.16万元，同比上升224.07%；单季度扣 非净利润123.64万元，同比上升118.23%；负债率29.86%，投资收益16.76万元，财务费用-52.36万元， 毛利率40.19%。迈得医疗（688310）主营业务：医用耗材智能装备的研发、生产、销售和服务,有效整 合医疗器械产品工艺、自动化、软件等方面的技术,形成独特的产品与服务优势,为医用耗材生产企业提 供自动化成套设备和软件服务整体式解决方案。 证券之星消息，截至2026年1月9日收盘，迈得医疗(688310)报收于16.13元，上涨1.13%，换手率1.6%， 成交量2.66万手，成交额4252.79万元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成 ...